ClinicalTrials.gg
Active, not recruitingNCT05704049IZALCOUpdated Dec 29, 2025

A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

A Phase 2 interventional study of Isatuximab and Carfilzomib in Relapsed/Refractory Multiple Myeloma, sponsored by Sanofi. Active, not recruiting at 23 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-29.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
118
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing isatuximab in Multiple Myeloma — 15 open to participants now, 34 under way, 9 of them phase 3. isatuximab · Multiple Myeloma.

Enrollment
11th of 50
118 · median 55
Started
2023
with 8 others
Phase 2
25 of 50
10 open now
Primary completion
2025-12
later than 7 of 33 live
Registered
37th of 50
by date
Lead sponsor
13 of 50
Sanofi

Among the 50 studies testing isatuximab in Multiple Myeloma, this one is the 11th largest by enrollment, is one of 9 that started in 2023, is one of 25 in phase 2, reaches primary completion later than 7 of the 33 other live ones, and was the 37th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

15 of the 50 studies testing isatuximab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About isatuximab

isatuximab: first FDA approval 2020 (SARCLISA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing isatuximab in Multiple Myeloma, or all of them as a file.
02

Study summary

The main purpose of this study is to measure the efficacy (Myeloma response) of subcutaneous (SC) isatuximab treatment in combination with carfilzomib and dexamethasone in adult participants with RRMM having received 1 to 3 prior lines of therapy, and to characterize the PK of isatuximab in combination with carfilzomib and dexamethasone after manual and On Body Delivery System (OBDS) administration. After confirmation of the feasibility of SC isatuximab by manual administration, patient will be randomized to 1 of the 2 delivery methods of SC isatuximab.

Read the detailed description

The duration of the study for a participant will include a period for screening of up to 28 days. A cycle duration is 28 days. Participants will be allowed to continue therapy until disease progression, unacceptable adverse events (AEs), participant request to discontinue treatment, or any other reason, as well as the study treatment is commercially available and reimbursed in the participant's country, or is available from another source, whichever is first. The overall study duration will be of approximately 45 months.

03

Conditions studied

  • Relapsed/Refractory Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must have a documented diagnosis of multiple myeloma (MM)

  • Participants with defined as at least one of the following:

    • Serum M-protein ≥0.5 g/dL measured using serum protein immunoelectrophoresis and/or
    • Urine M-protein ≥200 mg/24 hours measured using urine protein immunoelectrophoresis and/or
    • Serum free light chain (FLC) assay: Involved FLC assay ≥10 mg/dL (≥100 mg/L) and an abnormal serum FLC ratio (\<0.26 or >1.65).
  • Participant with MM with at least 1 and no more than 3 prior lines of therapy.
  • A female participant is eligible to participate if she is not pregnant, not breastfeeding, and either is not a female of (FCBP) or agrees to practice complete abstinence or use approved methods.
  • Male participants agree to practice true abstinence or agree to use approved contraception methods while receiving study treatment, during dose interruptions and at least 5 months following study treatment discontinuation, even if has undergone a successful vasectomy.
  • Capable of giving signed .

Exclusion criteria

Exclusion Criteria:

  • Primary MM defined as participants who have never achieved at least a minimal response (MR) with any treatment during the disease course
  • Participants with prior anti-CD38 treatment if: a) administered \<9 months before first isatuximab administration or randomization as applicable or, b) Intolerant to the anti-CD38 previously received
  • Prior treatment with carfilzomib
  • Known history of allergy to captisol (a cyclodextrin derivative used to solubilize carfilzomib), prior to sucrose, histidine (as base and hydrochloride salt), polysorbate 80, or any of the components (active substance or ) of study treatment that are not amenable to premedication with , or intolerance to arginine and Poloxamer 188 that would prohibit further treatment with these agents
  • Uncontrolled or active infection with hepatitis A, B, and C virus; known acquired immunodeficiency syndrome (AIDS)-related illness; active primary amyloid light chain (AL) amyloidosis
  • Any severe acute or chronic medical condition which could impair the ability of the participant to participate in the study or interfere with interpretation of study results (eg, systemic infection unless specific anti-infective therapy is employed) or participant unable to comply with the study procedures.

The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
118 participants (actual)

Study arms

  • Experimental
    Cohort 1: manual administration

    Isatuximab will be administered manually for 8 minutes on Day 1 of Cycle 1 followed by 6 minutes from Day 8 of Cycle 1 and thereafter, in combination with carfilzomib and dexamethasone. Participants may receive other treatments as rescue medication or background medication.

    Drug: Isatuximab · Drug: Carfilzomib · Drug: Dexamethasone · Drug: Dexamethasone IV · Drug: Montelukast · Drug: Acetaminophen · Drug: Diphenhydramine · Drug: Methylprednisolone

  • Experimental
    Part 1 Cohort 2: manual administration

    Isatuximab will be administered manually for 6 minutes on Day 1 of Cycle 1 and thereafter, in combination with carfilzomib and dexamethasone. Participants may receive other treatments as rescue medication or background medication.

    Drug: Isatuximab · Drug: Carfilzomib · Drug: Dexamethasone · Drug: Dexamethasone IV · Drug: Montelukast · Drug: Acetaminophen · Drug: Diphenhydramine · Drug: Methylprednisolone

  • Experimental
    Part 2 Cohort 3 Randomized Cohort: OBDS to manual

    Isatuximab will be administered in combination with carfilzomib and dexamethasone. Isatuximab will be administered via OBDS from Cycle 1 to 3. For Cycle 4 to 6, the method of administration will be switched for each participant from OBDS to manual administration. From Cycle 7 and onwards, participants can choose manual or OBDS. Participants may receive other treatments as rescue medication or background medication.

    Drug: Isatuximab · Drug: Carfilzomib · Drug: Dexamethasone · Drug: Dexamethasone IV · Drug: Montelukast · Drug: Acetaminophen · Drug: Diphenhydramine · Drug: Methylprednisolone

  • Experimental
    Part 2 Cohort 3 Randomized Cohort: Manual to OBDS

    Isatuximab will be administered in combination with carfilzomib and dexamethasone. Isatuximab will be administered manually from Cycle 1 to 3. For Cycle 4 to 6, the method of administration will be switched for each participant from manual to OBDS administration. From Cycle 7 and onwards, participants can choose manual or OBDS. Participants may receive other treatments as rescue medication or background medication.

    Drug: Isatuximab · Drug: Carfilzomib · Drug: Dexamethasone · Drug: Dexamethasone IV · Drug: Montelukast · Drug: Acetaminophen · Drug: Diphenhydramine · Drug: Methylprednisolone

  • Experimental
    Part 3 Cohort 4 Randomized Cohort: OBDS to manual

    Isatuximab will be administered in combination with carfilzomib and dexamethasone. Isatuximab will be administered via OBDS from Cycle 1 to 3. For Cycle 4 to 6, the method of administration will be switched for each participant from OBDS to manual administration. From Cycle 7 and onwards, participants can choose manual or OBDS. Participants may receive other treatments as rescue medication or background medication.

    Drug: Isatuximab · Drug: Carfilzomib · Drug: Dexamethasone · Drug: Dexamethasone IV · Drug: Montelukast · Drug: Acetaminophen · Drug: Diphenhydramine · Drug: Methylprednisolone

  • Experimental
    Part 3 Cohort 4: Randomized Cohort: manual to OBDS

    Isatuximab will be administered in combination with carfilzomib and dexamethasone. Isatuximab will be administered manually from Cycle 1 to 3. For Cycle 4 to 6, the method of administration will be switched for each participant from manual to OBDS administration. From Cycle 7 and onwards, participants can choose manual or OBDS. Participants may receive other treatments as rescue medication or background medication.

    Drug: Isatuximab · Drug: Carfilzomib · Drug: Dexamethasone · Drug: Dexamethasone IV · Drug: Montelukast · Drug: Acetaminophen · Drug: Diphenhydramine · Drug: Methylprednisolone

  • Experimental
    Part 3 Cohort 5 Randomized Cohort: OBDS to manual administration in Chinese participants

    Isatuximab will be administered in combination with carfilzomib and dexamethasone. Isatuximab will be administered via OBDS from Cycle 1 to 3. For Cycle 4 to 6, the method of administration will be switched for each participant from OBDS to manual administration. From Cycle 7 and onwards, participants can choose manual or OBDS. Participants may receive other treatments as rescue medication or background medication.

    Drug: Isatuximab · Drug: Carfilzomib · Drug: Dexamethasone · Drug: Dexamethasone IV · Drug: Montelukast · Drug: Acetaminophen · Drug: Diphenhydramine · Drug: Methylprednisolone

  • Experimental
    Part 3 Cohort 5 Randomized Cohort: manual to OBDS administration in Chinese participants

    Isatuximab will be administered in combination with carfilzomib and dexamethasone. Isatuximab will be administered manually from Cycle 1 to 3. For Cycle 4 to 6, the method of administration will be switched for each participant from manual to OBDS administration. From Cycle 7 and onwards, participants can choose manual or OBDS. Participants may receive other treatments as rescue medication or background medication.

    Drug: Isatuximab · Drug: Carfilzomib · Drug: Dexamethasone · Drug: Dexamethasone IV · Drug: Montelukast · Drug: Acetaminophen · Drug: Diphenhydramine · Drug: Methylprednisolone

Interventions

  • Investigational medicinal product; Pharmaceutical form: Solution for Subcutaneous administration; Route of administration: Subcutaneous

  • Investigational medicinal product; Pharmaceutical form: Powder for solution for infusion; Route of administration: Intravenous

    Also known as: Kyprolis

  • Investigational medicinal product/background treatment; ATC code: H02AB02; Pharmaceutical form: Tablet; Route of administration: Oral

  • Investigational medicinal product/background treatment; ATC code: H02AB02; Pharmaceutical form: Powder for solution for infusion; Route of administration: Intravenous

  • Background Treatment; ATC code: R03DC03; Pharmaceutical form: As per local commercial product; Route of administration: Oral

  • Background Treatment; ATC code: N02BE01; Pharmaceutical form: As per local commercial product; Route of administration: Oral or intravenous (IV)

  • Background Treatment; ATC code: R06AA02; Pharmaceutical form: As per local commercial product; Route of administration: Oral or IV

  • Background Treatment/Rescue medication; ATC code: H02AB04; Pharmaceutical form: As per local commercial product; Route of administration: IV

06

What researchers measure

Primary outcomes

  1. Overall response rate (ORR) - Cohorts 1 to 3

    ORR defined as the proportion of participants with stringent complete response (sCR), complete response (CR), very good partial response (VGPR), and partial response (PR) according to the 2016 International Myeloma Working Group (IMWG) criteria assessed by Independent Review Committee (IRC).

    Time frame: 6 months after the Last Participant In (LPI) i.e., approximately 16 months

  2. Maximum observed concentration (Cmax) over Cycle 1- Cohorts 4 to 5

    Time frame: Cycle 1 (28 days)

  3. Cumulative area under the curve over the first 4 weeks (AUC4weeks) of isatuximab treatment- Cohorts 4 to 5

    Time frame: Cycle 1 (28 days)

Secondary outcomes

  1. Proportion of participants preferring OBDS over manual administration of isatuximab SC at Day 15 of Cycle 6

    Patient preference for method of administration defined as the proportion of participants preferring OBDS over manual administration of isatuximab SC at Day 15 of Cycle 6 using the patient experience and satisfaction questionnaire version 2 (PESQ v2).

    Time frame: 6 months from LPI i.e., approximately 16 months

  2. Incidence rate of infusion reactions (IRs)

    Time frame: From the signing of the informed consent to 30 days following the last administration of any study treatment i.e., up to approximately 45 months

  3. Number of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and changes in laboratory parameters

    Time frame: From the signing of the informed consent to 30 days following the last administration of any study treatment i.e., up to approximately 45 months

  4. Incidence rate of injection site reactions (ISRs)

    Time frame: 18 months after LPI i.e., approximately 28 months

  5. PK concentration: trough plasma concentration (Ctrough)

    Blood samples will be collected for measurement of isatuximab concentrations.

    Time frame: Cycle 2 Day 1 and Cycle 6 Day 1 (1 Cycle = 28 days)

  6. Overall response rate (ORR)

    Proportion of participants with sCR, CR, VGPR, and PR according to the 2016 IMWG criteria assessed by investigator.

    Time frame: 6 months after the Last Participant In (LPI) i.e., approximately 16 months

  7. Duration of response (DOR)

    DOR defined as time from date of first IRC-determined response for participants achieving PR or better to first documentation of progressive disease (PD) determined by IRC or death, whichever occurred first, for Cohorts 1 to 3. For Cohorts 4-5, the time from date of first investigator determined response for participants achieving PR or better to first documentation of progressive disease (PD) determined by investigator or death, whichever occurred first.

    Time frame: 6 months after the Last Participant In (LPI) i.e., approximately 16 months

  8. Time to first response (TT1R)

    TT1R defined as time from first investigational medicinal product (IMP) administration or randomization to first IRC determined response (PR or better) that is subsequently confirmed, for Cohorts 1 to 3. For cohorts 4-5, the time from first IMP administration or randomization to first investigator determined response (PR or better) that is subsequently confirmed.

    Time frame: 6 months after the Last Participant In (LPI) i.e., approximately 16 months

  9. Time to best response (TTBR)

    TTBR defined as time from first IMP administration or randomization to first occurrence of IRC determined best response (PR or better) that is subsequently confirmed, for Cohorts 1 to 3. For cohorts 4-5, the time from first IMP administration or randomization to first occurrence of investigator determined best response (PR or better) that is subsequently confirmed.

    Time frame: 6 months after the Last Participant In (LPI) i.e., approximately 16 months

  10. Progression free survival (PFS)

    PFS defined as time from the date of first IMP administration or randomization to the date of first documentation of PD as determined by IRC for Cohorts 1 to 3 and by Investigator for all cohorts, or the date of death from any cause, whichever comes first.

    Time frame: 18 months after LPI i.e., approximately 28 months

  11. Overall survival (OS)

    OS defined as time from the date of first IMP administration or randomization to death from any cause.

    Time frame: 18 months after LPI i.e., approximately 28 months

  12. Incidence of participants with anti-drug antibodies (ADA) against isatuximab

    Time frame: From Cycle 1 Day 1 to follow-up (90 days from last administration) i.e., approximately 13 months (1 Cycle = 28 days)

  13. Patient Expectations Questionnaire at Baseline (PEQ-BL v2) with isatuximab administered subcutaneously

    PEQ-BL v2 is a participant assessed questionnaire. It will be completed at baseline prior to study treatment administration or other study related procedures. This questionnaire has been designed to assess the expectations of the participants regarding both the treatment (side effects, worth taking) and the administration method (confidence, comfortability, pain, side effects, potential time-savings), as well as to understand previous treatment experience from the participant (experience with injection methods for oncology medication).

    Time frame: Baseline

  14. Patient experience and satisfaction questionnaires (PESQ v2) with isatuximab administered subcutaneously

    PESQ v2 is a participant assessed questionnaire. It has been designed to follow up on participant experience and satisfaction regarding the treatment (side effects, worth taking and overall satisfaction) and the administration method (confidence, comfortability, pain, side effects, potential time-savings and overall satisfaction). The PESQ v2 includes items to assess preference on subcutaneous injection method. This questionnaire has been developed using industry standard for instrument development and has been debriefed and adapted based on qualitative interviews with oncology patients. The more general treatment expectations instrument (v1) was further adapted and debriefed with patients to assess manual and OBDS subcutaneous delivery (v2). The PESQ v2 contains a total of 9 items. There are 6 items that are administered for the duration of treatment, and 3 preference items administered only after patient experience of both manual and OBDS.

    Time frame: 18 months after LPI i.e., approximately 28 months

  15. Health state utility assessed using Health Resource Utilization and Productivity Questionnaire (HRUPQ)

    Medical resource utilization and participant productivity will be collected from participants through a specific questionnaire developed by Sanofi for cohorts 1,2, 3, and 5. The data collected include number, nature (emergency or routine) and duration of hospitalizations, emergency room visits and outpatient medical encounters and employment history.

    Time frame: 18 months after LPI i.e., approximately 28 months

  16. Health Related Quality of Life (HRQL)

    HRQL is assessed for cohorts 1, 2, and 3 using the European Organization for Research and Treatment of Cancer (EORTC) myeloma module with 20 items (QLQ-MY20) and EORTC quality of life questionnaire with 30 questions (QLQ-C30); a total of 50 items. The EORTC QLQ-C30 provides a comprehensive assessment of the principal HRQL dimensions identified as relevant by cancer patients. The EORTC QLQ-MY20 is to be used in conjunction with the EORTC QLQ-C30 to assess symptoms and side effects due to the treatment or the disease which impact HRQL in participants with MM.

    Time frame: 18 months after LPI i.e., approximately 28 months

  17. European Quality of Life Group questionnaire with 5 dimensions and 5 levels per dimension (EQ-5D-5L)

    Health status is assessed for cohorts 1, 2, and 3, using the EQ-5D-5L, a standardized measure of health status that provides a simple, generic measure of health utility, and consists of 2 sections: descriptive and VAS. The descriptive system consists of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The VAS records the respondent's self-rated health on a 20 cm vertical VAS with endpoints labelled 'the best health you can imagine' and 'the worst health you can imagine'. This information can be used as a quantitative measure of health as judged by the individual respondents.

    Time frame: 18 months after LPI i.e., approximately 28 months

07

Study locations

23 sites
  • Investigational Site Number : 0360002
    Wollongong, New South Wales 2500, Australia
  • Investigational Site Number : 0360001
    Melbourne, Victoria 3065, Australia
  • Hospital Mae de Deus Site Number : 0760002
    Porto Alegre, Rio Grande do Sul 90880-480, Brazil
  • Clinica São Germano- Site Number : 0760003
    São Paulo, 04537-080, Brazil
  • Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo- Site Number : 0760001
    São Paulo, 05403-000, Brazil
  • Investigational Site Number : 1560006
    Changsha, 410013, China
  • Investigational Site Number : 1560002
    Guangzhou, 510060, China
  • Investigational Site Number : 1560005
    Nanchang, 330006, China
  • Investigational Site Number : 1560004
    Shenyang, 110004, China
  • Investigational Site Number : 1560001
    Tianjin, 300020, China
  • Investigational Site Number : 1560007
    Tianjin, 300060, China
  • Investigational Site Number : 1560003
    Wuhan, 430030, China
  • Investigational Site Number : 2030002
    Brno, 625 00, Czechia
  • Investigational Site Number : 2030004
    Olomouc, 779 00, Czechia
  • Investigational Site Number : 2030003
    Ostrava, 708 52, Czechia
  • Investigational Site Number : 2030001
    Prague, 128 08, Czechia
  • Investigational Site Number : 3000001
    Athens, 106 76, Greece
  • Investigational Site Number : 3000002
    Athens, 115 28, Greece
  • Investigational Site Number : 3920001
    Kashiwa, Chiba 277-8577, Japan
  • Investigational Site Number : 3920002
    Okayama, 701-1192, Japan
  • Investigational Site Number : 6200001
    Braga, 4710-243, Portugal
  • Investigational Site Number : 6200004
    Lisbon, 1400-038, Portugal
  • Investigational Site Number : 6200005
    Lisbon, 1649-035, Portugal
08

References and documents

Publications

  • Parmar G, Capra M, Seguro F, Hungria V, Dimopoulos MA, Delimpasi S, Minarik J, Spicka I, Pour L, Marques H, Esteves G, Sunami K, Yuda J, Hajek R, Mihalyova J, Soufflet C, Yu D, Benlhassan K, Koch V, Comerford E, Cordero P, Suzan F, Quach H. Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma: results of the Phase 2 study IZALCO. Blood Cancer J. 2025 Dec 27;16(1):16. doi: 10.1038/s41408-025-01436-0. PubMed 41455697 ↗

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Dec 2025, 32 months.

Of 93 industry-sponsored phase 2 interventional studies under Multiple Myeloma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 77. This study's 32 months is below that.

Counting every sponsor, half of 506 studies reached it within 57 months; a quarter within 35 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2023
First posted
Jan 30, 2023
StartActual
Apr 5, 2023
Primary completionActual
Dec 22, 2025
CompletionEst.
May 12, 2028
Last update
Dec 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05704049
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jan 30, 2023
Start date
Apr 5, 2023
Primary completion
Dec 22, 2025
Completion
May 12, 2028 (estimated)
Last update
Dec 29, 2025

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Isatuximab · Carfilzomib · Dexamethasone

Start the discussion